Money
Briefing: Abbott Laboratories (ABT) Unveils XIENCE Skypoint to Advance Cardiovascular Treatment in India
Strategic angle: Abbott Laboratories introduces a new product aimed at improving cardiovascular care in the Indian market.
Editorial Staff
1 min read
Updated about 1 month ago
Abbott Laboratories has announced the introduction of XIENCE Skypoint, a product aimed at advancing cardiovascular treatment in India.
This new offering is expected to enhance the existing healthcare infrastructure by providing improved treatment options for patients with cardiovascular conditions.
The launch reflects Abbott's commitment to expanding its portfolio in emerging markets, addressing the growing demand for advanced medical technologies.